SCHEMBL6000247

SCHEMBL6000247

CCCCOC(=O)OCn1nc(C(=O)O)c(C(=O)c2cc(OC)c(OC)cc2N)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 5/20 0.36
HSD17B10 Q99714 3/20 0.36
KMT2A Q03164 5/20 0.35
MEN1 O00255 3/20 0.33
CYP3A4 P08684 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
F2 P00734 1/20 0.33
ALOX15 P16050 1/20 0.33
HTR4 Q13639 3/20 0.33
MAPT P10636 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
POLB P06746 1/20 0.32
CYP2D6 P10635 1/20 0.32
HTR3A P46098 1/20 0.32
TP53 P04637 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5512857 0.90 KDM4E (0.38) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL5524869 0.87 KDM4E (0.39) KDM4EALDH1A1HSD17B10KMT2AMAPT
SCHEMBL6000183 0.85 KDM4E (0.39) KDM4EALDH1A1KMT2AMEN1
SCHEMBL5516130 0.81 KDM4E (0.42) KDM4EALDH1A1HSD17B10MAPTNPSR1
SCHEMBL5517606 0.77 KDM4E (0.38) KDM4EALDH1A1MAPTNPSR1POLB
SCHEMBL5512764 0.77 TNF (0.39) KDM4EALDH1A1CYP3A4CYP2C19MAPT
SCHEMBL5511478 0.77 TNF (0.39) KDM4EALDH1A1CYP3A4CYP2C19MAPT
SCHEMBL5511980 0.76 LMNA (0.42) ALDH1A1KMT2AMEN1CYP3A4MAPT
SCHEMBL5508711 0.75 KDM4E (0.38) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL5512207 0.75 MYC (0.42) KDM4EALDH1A1HSD17B10MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents MEIJI SEIKA PHARMA CO., LTD. (JP) 2006-04-06 US disclosed
EP-1026167-B1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND ANTIALLERGIC AGENTS MEIJI SEIKA KAISHA (JP) 2003-03-05 EP disclosed
EP-1026167-A1 TRICYCLIC TRIAZOLOBENZAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND ANTIALLERGIC MEIJI SEIKA KAISHA LTD. (JP) 2000-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074074-A1 Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents HRH4, CYP2D6, CYP2B6 KDM4E 752/4885ALDH1A1 959/4885HSD17B10 859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.